Steven Gelone
Directeur/Membre du Conseil chez NABRIVA THERAPEUTICS PLC
Fortune : 20 454 $ au 31/07/2023
Postes actifs de Steven Gelone
Sociétés | Poste | Début | Fin |
---|---|---|---|
NABRIVA THERAPEUTICS PLC | Directeur/Membre du Conseil | 01/03/2021 | - |
Directeur des opérations | 24/07/2018 | 15/01/2023 | |
Directeur Technique/Scientifique/R&D | 30/06/2017 | 24/07/2018 | |
Corporate Officer/Principal | 23/06/2017 | 30/06/2017 | |
President | 24/07/2018 | 15/01/2023 |
Historique de carrière de Steven Gelone
Anciens postes connus de Steven Gelone
Sociétés | Poste | Début | Fin |
---|---|---|---|
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Directeur Technique/Scientifique/R&D | - | 30/06/2017 |
Corporate Officer/Principal | 01/01/2014 | - | |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/01/2005 | 01/01/2014 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Directeur Technique/Scientifique/R&D | 01/01/2002 | 01/01/2003 |
GSK PLC | Directeur Technique/Scientifique/R&D | 01/01/2000 | 01/01/2002 |
SPARK THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2014 | - |
Formation de Steven Gelone
Temple University (Pennsylvania) | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Autriche | 2 |
Irlande | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 7 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
NABRIVA THERAPEUTICS PLC | Health Technology |
GSK PLC | Health Technology |
Entreprise privées | 4 |
---|---|
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
- Bourse
- Insiders
- Steven Gelone
- Expérience